Key result
Oral amiodarone pretreatment boosts electrical cardioversion success to 88% and reduces AF recurrence.
Why the study?
Direct current cardioversion for persistent atrial fibrillation has limited success and high early recurrence, and pre-treatment strategies to improve efficacy are needed.
Does pre-treatment with oral amiodarone or glucose-insulin-potassium improve the efficacy of electrical cardioversion and maintain sinus rhythm in patients with persistent atrial fibrillation?
RCT (n=92)
prospectively randomized
Does pre-treatment with oral amiodarone or glucose-insulin-potassium improve the efficacy of electrical cardioversion and maintain sinus rhythm in patients with persistent atrial fibrillation?
Pre-treatment with oral amiodarone significantly increases the efficacy of electrical cardioversion and reduces 2-month atrial fibrillation recurrence compared to diltiazem or glucose-insulin-potassium.
Amiodarone pre-treatment is preferable before cardioversion in persistent AF; reinforces its superiority over GIK or control in this RCT.
AIMS: Direct current cardioversion of persistent atrial fibrillation is one of the most widely used and effective treatments for the restoration of sinus rhythm, but may be hampered by a low success rate and a high percentage of early recurrence. Pre-treatment with amiodarone or a glucose-insulin-potassium solution could improve the efficacy of electrical cardioversion by reversing the partially depolarized diastolic potential of the subsidiary pacemakers in atrial fibrillation. In a controlled randomized study, we assessed the effectiveness of electrical cardioversion in patients with persistent atrial fibrillation after pre-treatment with amiodarone or potassium infusion and the efficacy of amiodarone in maintaining sinus rhythm after electrical cardioversion. METHODS AND RESULTS: Ninety-two patients with persistent atrial fibrillation (>2 weeks duration) were prospectively randomized into three matched groups: A (n=31, oral amiodarone 400 mg. day(-1)1 month before and 200 mg. day(-1)2 months after cardioversion), B (n=31, 180 mg. day(-1)oral diltiazem 1 month before and 2 months after cardioversion and 80 mmol potassium, 50 UI insulin in 500 ml 30% glucose solution 24 h before cardioversion) and C (n=30, control patients, 180 mg. day(-1)oral diltiazem 1 month before and 2 months after cardioversion). Before cardioversion all patients were under 4 weeks effective oral anticoagulant therapy (warfarin). Before electrical cardioversion, the rate of spontaneous conversion to sinus rhythm was higher in group A (25%) than groups B (6%) or C (3%) (P<0.005). Electrical cardioversion was more successful in group A (88%) than groups B (56%) or C (65%) (P<0.05), while the electrical thresholds for effective cardioversion were lower in group B than the other groups (P<0.05). Twenty-four hours after cardioversion, the early recurrence of atrial fibrillation was similar in the three groups (P=ns), while at 2 months the recurrence rate was lower in group A (32%) than groups B (56%) or C (52%) (P<0.01). CONCLUSION: Pre-treatment with low-dose oral amiodarone, compared with oral diltiazem or glucose-insulin-potassium treatments, induces a significantly high percentage of instances of spontaneous conversion, increases electrical cardioversion efficacy and reduces atrial fibrillation recurrence.
No takes yet. Share an insight, caveat, or question.
Alessandro Capucci (2000) conducted an RCT in persistent atrial fibrillation (n=92). Oral amiodarone vs. Oral diltiazem (control) or glucose-insulin-potassium was evaluated on successful electrical cardioversion (p=<0.05). Pre-treatment with oral amiodarone increased electrical cardioversion success (88% vs 65% for control; P<0.05) and reduced atrial fibrillation recurrence at 2 months (32% vs 52%; P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: